Investor Video Series: A Deeper Look at the Occuity AX1 Axiometer
- Richard Kadri-Langford
- 1 day ago
- 2 min read
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.Take 2 minutes to learn more: https://europe.republic.com/pages/risk-warnings
As part of our ongoing investor video series showcasing the technology, products and vision behind Occuity, our latest instalment takes a closer look at the AX1 Axiometer — the handheld, non-contact device set to transform the growing global market for childhood myopia management.
The AX1 represents one of the most significant commercial opportunities within our product portfolio, and this video provides a clear explanation of why axial length matters, how the AX1 works, and where it fits within the expanding clinical and consumer demand for earlier detection and better monitoring of myopia progression.
Why the AX1 Matters for Investors
Childhood myopia is rising sharply worldwide, with forecasts indicating that half of the global population will be myopic by 2050. This surge is creating a major need for accessible, reliable axial-length measurement — the most accurate biomarker for tracking disease progression.
The AX1 has been engineered to meet this need by providing:
A handheld, non-contact alternative to bulky, clinic-bound biometers
A child-friendly workflow, supporting large-scale screening and routine monitoring
Ease of adoption, enabling optometrists and high-street practices to integrate axial-length measurement without specialist equipment or dark-room environments
With early interest from major global players in the myopia-management sector and a market growing at pace, the AX1 is positioned to become a cornerstone product in Occuity’s device portfolio.
What You’ll Learn in the Video
This episode of our investor series includes insights from the team behind the AX1, highlighting:
The clinical and commercial importance of axial length
Current limitations in the market — and how the AX1 overcomes them
Why a handheld, non-contact approach unlocks new distribution opportunities
How the AX1 sits within our wider platform strategy and long-term Oculomics roadmap
For investors following Occuity’s trajectory, this is an excellent opportunity to understand the AX1’s role within our near-term and long-term growth strategy.
Watch the AX1 Investor Video
If you haven’t yet explored the rest of our investor video series, we encourage you to do so — each episode dives into a different part of our technology platform and commercial pipeline, from the PM1 Pachymeter to our groundbreaking Oculomics devices.
Join Occuity’s Investment Round
Occuity is currently raising on Republic. To learn more:
👉 Download our pitch deck
👉 Ask us questions directly
We welcome all investors who want to be part of transforming eye-based health screening worldwide.
Comments